Drug Profile
AMG 220
Alternative Names: C-326Latest Information Update: 10 Sep 2008
Price :
$50
*
At a glance
- Originator Avidia
- Developer Amgen
- Class Anti-inflammatories; Proteins
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Crohn's disease
Most Recent Events
- 25 Oct 2006 Avidia has been acquired by Amgen
- 22 Sep 2006 Phase-I clinical trials in Crohn's disease in Australia (IV)